Clinical manufacture of FT819: Use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy Meeting Abstract

  

Authors:	Yuan, X.; Clarke, R.; Lai, Y. S.; Chang, C. W.; Yang, B. H.; Hsia, G.; Abujarour, R.; Lee, T.; van der Stegen, S.; Shaked, H.; Jalloh, A.; Moreno, S.; O'Rourke, J.; Sung, E.; Gutierrez, A.; Rezner, B.; Eberhart, M.; Magdaleno, R.; Wang, X.; Senechal, B.; Sikder, D. S.; Farnan, D.; Plavsic, M.; Bressi, J.; Rivière, I.; Valamehr, B.
Abstract Title:	Clinical manufacture of FT819: Use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Keywords:	cancer immunotherapy; cell therapy; pluripotent stem cell; allogeneic; induced; production; ipsc; cd19; cgmp; engineered; car-t; manufacturing; off-the-shelf; clonal master ipsc line; ft819
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736398807004
DOI:	10.1182/blood-2021-152985
PROVIDER:	wos
Notes:	Meeting Abstract: 1766 -- Hybrid meeting, also took place online -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/198968